C4 Therapeutics and Merck KGaA Partner to Discover Protein Degraders Against Oncogenic Proteins

By PharmaShots

Shots: C4 Therapeutics and Merck KGaA have signed a strategic license & collaboration agreement for the discovery of two targeted protein degraders against oncogenic proteins of interest from the former's internal discovery pipeline As per the agreement, C4T will ob

You are viewing a robot-friendly page.Click hereto reload in standard format.